Iloperidone: A new drug for the treatment of schizophrenia
- Iloperidone: Does it have a meaningful place in therapy? // American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p297
No abstract available.
- OLANZAPINE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p620
The article presents information on olanzapine, an antipsychotic drug, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.
- PHENOTHIAZINES. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p660
The article presents information on phenothiazines, antipsychotic drugs, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.
- Once-daily treatment of schizophrenia. // Clinical Advisor;Apr2011, Vol. 14 Issue 4, p35
The article focuses on Latuda with lurasidone and its efficacy in schizophrenia. It mentions that the efficacy of lurasidone is mediated on a combination of central dopamine and serotonin receptor antagonism and is established in six-week placebo-controlled studies in adults. The study uses...
- Antipsychotics/general anaesthetics/ mepivacaine/vecuronium bromide. // Reactions Weekly;1/5/2013, Issue 1433, p9
The article describes the case of a 54-year-old man who experienced severe hypotension, ventricular fibrillation and cardiac arrest while receiving treatment with bromperidol, periciazine, fentanyl, propofol, sevoflurane, mepivacaine and vecuronium bromide.
- Olanzapine-induced Orthostatic Hypotension. Jana, Amlan Kusum; Praharaj, Samir Kumar; Roy, Nirmalya // Clinical Psychopharmacology & Neuroscience;Apr2015, Vol. 13 Issue 1, p113
Olanzapine is an atypical antipsychotic which is efficacious in the treatment of schizophrenia. The adverse effect profile for olanzapine is benign except for higher rates of metabolic events. Orthostatic hypotension is less commonly reported with olanzapine as compared to first-generation and...
- Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. Graff-Guerrero, Ariel; Rajji, Tarek K.; Mulsant, Benoit H.; Shinichiro Nakajima; Caravaggio, Fernando; Takefumi Suzuki; Hiroyuki Uchida; Gerretsen, Philip; Mar, Wanna; Pollock, Bruce G.; Mamo, David C. // JAMA Psychiatry;Sep2015, Vol. 72 Issue 9, p927
IMPORTANCE: Patients with late-life schizophrenia (LLS) are highly susceptible to antipsychotic adverse effects. Treatment guidelines endorse lower antipsychotic doses. However, the optimal dose of antipsychotics and associated dopamine D2/3 receptor (D2/3R) occupancies remain largely unexplored...
- IN SESSION with Anil Malhotra, MD: Pharmacogenetics of Schizophrenia. Sussman, Norman // Primary Psychiatry;Jul2010, Vol. 17 Issue 7, p31
An interview with Doctor Anil Malhotra, director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, New York, is presented. When asked about the difference between genomics and pharmacogenetics, he states that pharmacogenetics refers to the effects of the treatment to a patient...
- Schizophrenics' Improvement: Maybe It's the New Meds. Or Maybe Not. // Behavior Analysis Digest International;Fall2010, Vol. 22 Issue 3, p12
The article discusses research on cognitive gains in schizophrenic patients given newer antipsychotic medications.